Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Drug Metab Toxicol. 2008 Mar;4(3):287-304. doi: 10.1517/17425255.4.3.287 .

An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability.

Author information

1
Professor of Medicine and Public Health Sciences Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA. jrcrouse@wfubmc.edu

Abstract

BACKGROUND:

The HMG Co-A reductase inhibitors (statins) are the most efficacious agents for lowering cholesterol. Statins reduce clinical cardiovascular events and are generally well tolerated.

OBJECTIVE:

To review the efficacy and safety of rosuvastatin, the newest and most potent of the approved statins.

METHODS:

A comprehensive (PubMed) search was performed to identify relevant publications up to May 2007.

RESULTS/CONCLUSIONS:

Rosuvastatin reduces LDL cholesterol (LDL-C) by up to 50%, and by 70% when combined with ezetimibe. Rosuvastatin also reduces plasma triglycerides and increases HDL-C, and slows atherosclerosis progression in coronary and carotid arteries in both low-risk and high-risk individuals. Tolerability is comparable with other statins. Clinical trials to evaluate cardiovascular outcomes have recently been published (CORONA) or are underway.

PMID:
18363544
DOI:
10.1517/17425255.4.3.287
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center